Identification of genetic variants can predict the predisposition of the paediatric ALL patients in developing L-asparaginase resistance or adverse reactions, helping establish a more suitable and rational treatment regimen individually tailored for each of the patients, in turn maximising the efficacy of the antineoplastic agent (37). This evidence concerns the gene ASPG and acute lymphoblastic leukemia.